Cover Image
Market Research Report
Product code 
1038534

Global Glioblastoma Multiforme Treatment Market 2022-2026

Published: | TechNavio (Infiniti Research Ltd.) | 120 Pages | Delivery time: 1-2 business days

Price

Back to Top
Global Glioblastoma Multiforme Treatment Market 2022-2026
Published: October 22, 2021
TechNavio (Infiniti Research Ltd.)
Content info: 120 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents

Technavio has been monitoring the glioblastoma multiforme treatment market and it is poised to grow by $ 1.41 bn during 2022-2026, progressing at a CAGR of 8.48% during the forecast period. Our report on the glioblastoma multiforme treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing incidence of glioblastoma multiforme and favorable government initiatives. In addition, the increasing incidence of glioblastoma multiforme is anticipated to boost the growth of the market as well.

The glioblastoma multiforme treatment market analysis includes the end-user segment and geographic landscape.

Technavio's glioblastoma multiforme treatment market is segmented as below:

By End-user

  • hospitals
  • clinics
  • ambulatory surgical centers

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the increasing geriatric populationas one of the prime reasons driving the glioblastoma multiforme treatment market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on glioblastoma multiforme treatment market covers the following areas:

  • Glioblastoma multiforme treatment market sizing
  • Glioblastoma multiforme treatment market forecast
  • Glioblastoma multiforme treatment market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading glioblastoma multiforme treatment market vendors that include Amgen Inc., Amneal Pharmaceuticals Inc., Angiochem Inc., Arbor Pharmaceuticals LLC, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., Pfizer Inc., Sumitomo Dainippon Pharma Co. Ltd., and Sun Pharmaceutical Industries Ltd. Also, the glioblastoma multiforme treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR71331

Table of Contents

  • Executive Summary
    • Market overview
  • Market Landscape
    • Market ecosystem
    • Value chain analysis
  • Market Sizing
    • Market definition
    • Market segment analysis
    • Market size 2021
    • Market outlook: Forecast for 2021 - 2026
  • Five Forces Analysis
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
  • Market Segmentation by End-user
    • Market segments
    • Comparison by End-user
    • Hospitals - Market size and forecast 2021-2026
    • Clinics - Market size and forecast 2021-2026
    • Ambulatory surgical centers - Market size and forecast 2021-2026
    • Market opportunity by End-user
  • Customer landscape
  • Geographic Landscape
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2021-2026
    • Europe - Market size and forecast 2021-2026
    • Asia - Market size and forecast 2021-2026
    • ROW - Market size and forecast 2021-2026
    • Key leading countries
    • Market opportunity By Geographical Landscape
    • Market drivers
    • Market challenges
    • Market trends
  • Vendor Landscape
    • Vendor landscape
    • Landscape disruption
  • Vendor Analysis
    • Vendors covered
    • Market positioning of vendors
    • Amgen Inc.
    • Amneal Pharmaceuticals Inc.
    • Angiochem Inc.
    • Arbor Pharmaceuticals LLC
    • Bristol-Myers Squibb Co.
    • F. Hoffmann-La Roche Ltd.
    • Merck and Co. Inc.
    • Pfizer Inc.
    • Sumitomo Dainippon Pharma Co. Ltd.
    • Sun Pharmaceutical Industries Ltd.
  • Appendix
    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

Exhibits

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2021 - 2026 ($ million)
  • 13: Global market: Year-over-year growth 2021 - 2026 (%)
  • 14: Five forces analysis 2021 & 2026
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2021
  • 21: End-user - Market share 2021-2026 (%)
  • 22: Comparison by End-user
  • 23: Hospitals - Market size and forecast 2021-2026 ($ million)
  • 24: Hospitals - Year-over-year growth 2021-2026 (%)
  • 25: Clinics - Market size and forecast 2021-2026 ($ million)
  • 26: Clinics - Year-over-year growth 2021-2026 (%)
  • 27: Ambulatory surgical centers - Market size and forecast 2021-2026 ($ million)
  • 28: Ambulatory surgical centers - Year-over-year growth 2021-2026 (%)
  • 29: Market opportunity by End-user
  • 30: Customer landscape
  • 31: Market share By Geographical Landscape 2021-2026 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2021-2026 ($ million)
  • 34: North America - Year-over-year growth 2021-2026 (%)
  • 35: Europe - Market size and forecast 2021-2026 ($ million)
  • 36: Europe - Year-over-year growth 2021-2026 (%)
  • 37: Asia - Market size and forecast 2021-2026 ($ million)
  • 38: Asia - Year-over-year growth 2021-2026 (%)
  • 39: ROW - Market size and forecast 2021-2026 ($ million)
  • 40: ROW - Year-over-year growth 2021-2026 (%)
  • 41: Key leading countries
  • 42: Market opportunity By Geographical Landscape ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: Amgen Inc. - Overview
  • 50: Amgen Inc. - Business segments
  • 51: Amgen Inc. - Key offerings
  • 52: Amgen Inc. - Key customers
  • 53: Amgen Inc. - Segment focus
  • 54: Amneal Pharmaceuticals Inc. - Overview
  • 55: Amneal Pharmaceuticals Inc. - Business segments
  • 56: Amneal Pharmaceuticals Inc. - Key offerings
  • 57: Amneal Pharmaceuticals Inc. - Key customers
  • 58: Amneal Pharmaceuticals Inc. - Segment focus
  • 59:Angiochem Inc. - Overview
  • 60:Angiochem Inc. - Product and service
  • 61:Angiochem Inc. - Key offerings
  • 62:Angiochem Inc. - Key customers
  • 63:Angiochem Inc. - Segment focus
  • 64: Arbor Pharmaceuticals LLC - Overview
  • 65: Arbor Pharmaceuticals LLC - Product and service
  • 66: Arbor Pharmaceuticals LLC - Key offerings
  • 67: Arbor Pharmaceuticals LLC - Key customers
  • 68: Arbor Pharmaceuticals LLC - Segment focus
  • 69: Bristol-Myers Squibb Co. - Overview
  • 70: Bristol-Myers Squibb Co. - Product and service
  • 71: Bristol-Myers Squibb Co. - Key offerings
  • 72: Bristol-Myers Squibb Co. - Key customers
  • 73: Bristol-Myers Squibb Co. - Segment focus
  • 74: F. Hoffmann-La Roche Ltd. - Overview
  • 75: F. Hoffmann-La Roche Ltd. - Business segments
  • 76: F. Hoffmann-La Roche Ltd. - Key offerings
  • 77: F. Hoffmann-La Roche Ltd. - Key customers
  • 78: F. Hoffmann-La Roche Ltd. - Segment focus
  • 79: Merck and Co. Inc. - Overview
  • 80: Merck and Co. Inc. - Business segments
  • 81: Merck and Co. Inc. - Key offerings
  • 82: Merck and Co. Inc. - Key customers
  • 83: Merck and Co. Inc. - Segment focus
  • 84: Pfizer Inc. - Overview
  • 85: Pfizer Inc. - Business segments
  • 86: Pfizer Inc. - Key offerings
  • 87: Pfizer Inc. - Key customers
  • 88: Pfizer Inc. - Segment focus
  • 89: Sumitomo Dainippon Pharma Co. Ltd. - Overview
  • 90: Sumitomo Dainippon Pharma Co. Ltd. - Business segments
  • 91: Sumitomo Dainippon Pharma Co. Ltd. - Key offerings
  • 92: Sumitomo Dainippon Pharma Co. Ltd. - Key customers
  • 93: Sumitomo Dainippon Pharma Co. Ltd. - Segment focus
  • 94: Sun Pharmaceutical Industries Ltd. - Overview
  • 95: Sun Pharmaceutical Industries Ltd. - Product and service
  • 96: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 97: Sun Pharmaceutical Industries Ltd. - Key customers
  • 98: Sun Pharmaceutical Industries Ltd. - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations